#1 Clinical Trials Search in Europe

Autologous Adipose Tissue-Derived Stromal Vascular Fraction Cells

This article discusses ongoing clinical trials investigating the use of Autologous Adipose Tissue-Derived Stromal Vascular Fraction Cells (ADSVF) for treating different medical conditions. ADSVF is a type of cell therapy derived from a patient’s own fat tissue. These trials aim to evaluate the safety and effectiveness of ADSVF in addressing conditions such as urethral strictures, diabetic foot ulcers, scarred vocal folds, and Crohn’s disease-related perianal fistulas. The studies are in various phases and employ different administration methods to explore the potential benefits of this innovative treatment approach.

Table of Contents

What is Autologous Adipose Tissue-Derived Stromal Vascular Fraction (ADSVF)?

Autologous Adipose Tissue-Derived Stromal Vascular Fraction (ADSVF) is an innovative medical treatment that uses cells from a patient’s own fat tissue. The term “autologous” means the cells come from the patient’s own body, while “adipose tissue” refers to fat tissue. Stromal vascular fraction (SVF) is a complex mixture of cells found within fat tissue, including stem cells, immune cells, and other supportive cells[1].

Conditions Being Treated with ADSVF

Research is ongoing to explore the potential of ADSVF in treating various medical conditions. Current clinical trials are investigating its use in:

  • Urethral stricture: A narrowing of the urethra that can cause difficulty urinating[1].
  • Diabetic foot ulcers: Chronic wounds that occur in people with diabetes[2].
  • Scarred vocal folds: Damage to the vocal cords that can cause voice problems[3].
  • Perianal Crohn’s disease fistulas: Abnormal connections between the intestine and skin near the anus in patients with Crohn’s disease[4].

How ADSVF Works

ADSVF is believed to work through several mechanisms:

  1. Regeneration: The stem cells in ADSVF may help regenerate damaged tissues.
  2. Anti-inflammatory effects: ADSVF contains cells that can reduce inflammation in the treated area.
  3. Angiogenesis: ADSVF may promote the formation of new blood vessels, improving blood supply to the affected area.
  4. Immunomodulation: The cells in ADSVF can help regulate the immune response, potentially beneficial in conditions like Crohn’s disease.

How ADSVF is Administered

The process of ADSVF treatment typically involves:

  1. Fat harvesting: A small amount of fat is taken from the patient’s body, usually from the abdomen or thighs.
  2. Processing: The fat tissue is processed to isolate the stromal vascular fraction.
  3. Injection: The ADSVF is then injected into the affected area. For example:
    • For urethral strictures, it’s injected near the urethra[1].
    • For diabetic foot ulcers, it’s injected around the wound[2].
    • For vocal fold scars, it’s injected into the vocal folds[3].
    • For Crohn’s disease fistulas, it’s injected around the fistula tracts[4].

Current Clinical Trials

Several clinical trials are currently underway to evaluate the safety and effectiveness of ADSVF for various conditions:

  • A study for recurrent urethral stricture, comparing ADSVF injection to standard treatment[1].
  • A trial for diabetic foot ulcers that haven’t responded to standard care[2].
  • An investigation into ADSVF for treating scarred vocal folds and improving voice quality[3].
  • A study on the use of ADSVF combined with microfat for treating perianal fistulas in Crohn’s disease[4].

Safety and Side Effects

As ADSVF uses the patient’s own cells, the risk of rejection is low. However, potential side effects may include:

  • Pain or discomfort at the injection site
  • Bruising or swelling
  • Infection (though rare)

The ongoing clinical trials are closely monitoring patients for any adverse effects to ensure the safety of this treatment[1][2][3][4].

Future Research and Potential

ADSVF is an exciting area of research in regenerative medicine. Future studies may explore its use in other conditions and further refine the treatment process. As research progresses, we may gain a better understanding of how factors like the composition of ADSVF and individual patient characteristics affect treatment outcomes[4].

While ADSVF shows promise, it’s important to note that these treatments are still experimental. Patients should discuss all treatment options with their healthcare providers to determine the best approach for their individual situation.

Condition Trial Phase Administration Method Primary Endpoint
Recurrent Urethral Stricture Phase II Local injection during endoscopic urethrotomy Safety and tolerability at follow-up
Diabetic Foot Ulcer Phase II Local injection into/around ulcer Percentage of wounds completely healed by week 20
Scarred Vocal Folds Phase II Local injection into vocal folds Improvement in Voice Handicap Index at 6 months
Perianal Crohn’s Fistulas Phase II Local injection with microfat Clinical and MRI-confirmed closure of fistulas at week 24

FAQ

  • What are Autologous Adipose Tissue-Derived Stromal Vascular Fraction Cells? Autologous Adipose Tissue-Derived Stromal Vascular Fraction Cells (ADSVF) are cells obtained from a patient's own fat tissue. These cells contain a mixture of different cell types, including stem cells, which have the potential to promote healing and tissue regeneration.
  • What medical conditions are being studied using ADSVF in these clinical trials? The clinical trials are investigating the use of ADSVF for various conditions, including recurrent urethral strictures, diabetic foot ulcers, scarred vocal folds, and complex perianal fistulas in Crohn's disease patients.
  • How is ADSVF administered in these trials? The administration method varies depending on the condition being treated. For example, it may be injected locally into the affected area, such as around the urethra for strictures, into or around diabetic foot ulcers, into scarred vocal folds, or into perianal fistulas.
  • What are the main objectives of these clinical trials? The main objectives of these trials are to assess the safety and efficacy of ADSVF treatment compared to placebo or standard care. They aim to determine if ADSVF can improve healing, reduce symptoms, or enhance quality of life for patients with the targeted conditions.
  • Are there any common eligibility criteria across these trials? While specific criteria vary, common elements include being an adult, having a confirmed diagnosis of the condition being studied, and being in generally good health. Many trials also require patients to have tried and failed standard treatments before being eligible for ADSVF therapy.

Ongoing Clinical Trials on Autologous Adipose Tissue-Derived Stromal Vascular Fraction Cells

  • Study on the Safety of Using Autologous Stromal Vascular Fraction Cells and Micrograft for Treating Hard-to-Heal Ano-Perineal Fistulas in Crohn’s Disease Patients

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Treatment Study of Diabetic Foot Ulcers Using Autologous Stromal Vascular Fraction Cells for Patients with Non-healing Wounds

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Effectiveness of Autologous Adipose-Derived Stromal Vascular Fraction Cells for Patients with Scarred Vocal Folds

    Recruiting

    2 1
    Investigated drugs:
    France

  • Study of Autologous Adipose Tissue-Derived Stromal Vascular Fraction Cells and Microfat for Patients with Refractory Perianal Crohn’s Disease Fistulas

    Recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Safety of Autologous Adipose Tissue-Derived Stromal Vascular Fraction Cells for Patients with Recurrent Urethral Stricture

    Not yet recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    France

Glossary

  • Autologous: Derived from and used for the same individual. In this context, it means the cells are taken from the patient's own body.
  • Stromal Vascular Fraction (SVF): A mixture of cells obtained from fat tissue, including stem cells, immune cells, and other supportive cells, which may have regenerative properties.
  • Urethral stricture: A narrowing of the urethra (the tube that carries urine out of the body) that can cause difficulty urinating.
  • Diabetic foot ulcer: An open sore or wound that occurs in people with diabetes, typically on the bottom of the foot, and can be slow to heal.
  • Perianal fistula: An abnormal tunnel-like connection between the anal canal and the skin around the anus, often occurring in people with Crohn's disease.
  • Endoscopic urethrotomy: A surgical procedure to treat urethral strictures by cutting through the narrowed area using a special instrument inserted through the urethra.
  • Uroflowmetry: A test that measures the flow rate of urine during urination, used to assess urinary function.
  • Voice Handicap Index (VHI): A standardized questionnaire used to measure the impact of voice disorders on a person's quality of life.
  • Crohn's Disease Activity Index (CDAI): A tool used to quantify the symptoms of Crohn's disease and assess disease activity.
  • Microfat: Small particles of fat tissue used in some regenerative medicine procedures, often in combination with other treatments.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-of-autologous-adipose-tissue-derived-stromal-vascular-fraction-cells-for-patients-with-recurrent-urethral-stricture/
  2. http://clinicaltrials.eu/trial/study-on-treating-diabetic-foot-ulcers-with-autologous-adipose-tissue-derived-stromal-vascular-fraction-cells-for-patients-unresponsive-to-standard-care/
  3. http://clinicaltrials.eu/trial/study-on-the-effectiveness-of-autologous-adipose-derived-stromal-vascular-fraction-cells-for-patients-with-scarred-vocal-folds/
  4. http://clinicaltrials.eu/trial/study-of-autologous-adipose-tissue-derived-stromal-vascular-fraction-cells-and-microfat-for-patients-with-refractory-perianal-crohns-disease-fistulas/